Leadership Change

The ultra-luxury automaker's new CFO, Scott Durbin, brings a history of massive fundraising in biotech—a strategic hire signaling a major capital push.

Veea Inc. bolsters its leadership to capture the booming edge AI market, but can seasoned executives overcome daunting financial hurdles and fierce competition?

As Kyverna eyes a first-in-class approval for its CAR T-cell therapy, it brings in a legal and compliance veteran with a prosecutor's edge to clear the path.

With a pivotal drug approval on the horizon, Spruce Biosciences' appointment of a rare disease veteran signals a critical transition from R&D to commercial reality.

With new CEO Eric Augustyn, an active investor from its own ranks, BiggerPockets plans a major platform overhaul to fortify its market dominance.

Agiloft's hiring of Kristin Knox Esche isn't just a leadership change; it's a strategic bet on embedding the customer's voice into its innovation engine.

A public battle rages at Fermi Inc. as its former CEO attempts a hostile takeover, pitting his vision against the board's strategy for Project Matador.

Polaris appoints Sealed Air CEO Dustin Semach to its board, a move signaling a calculated pivot towards technology and financial rigor in its powersports strategy.

As private credit pulls back, PropTech firm Gumption expands its tech-driven financing platform to the West Coast, betting on a seasoned expert to succeed.

As Abigail Buckwalter takes the helm at Ocean Spray, the iconic cooperative bets on her global CPG expertise. Can she drive growth while honoring its farmer-owned roots?

Israel's Biond Biologics hires Dr. Giovanni Selvaggi, a seasoned drug developer, as CMO. The move signals a strategic shift to accelerate its unique 'first-in-class' immunotherapies through late-stage trials.

Hemlo Mining's appointment of capital markets veteran Eva Koci is more than a new face on the board. It's a strategic move to fortify governance and fund a new era of growth.

Sanofi taps AI-native biotech expert Paulo Fontoura to lead its global R&D, a high-stakes move to accelerate drug discovery after recent pipeline disappointments.

Claranova's sudden CFO change comes at a pivotal moment. We analyze the move's impact on its debt strategy and its pivot to a pure-play SaaS model.

With Japan facing a 'knowledge bomb' from a retiring workforce, Trupeer AI bets on a UiPath veteran to build the one thing enterprise AI is missing: context.

As complex litigation surges, CPT Group's appointment of a 28-year veteran isn't just a hire—it's a strategic move in a high-stakes, tech-driven industry.

As founder Roger Moore retires, Vision Marine completes its Nautical Ventures integration. This move signals a bold new chapter for the company's electric boating ambitions.

SPX Technologies executes a planned succession in its key D&M segment, betting on internal talent Eric Kaled to build on John Swann's legacy of growth.

XAI proposes a major sub-adviser shift for its XFLT and OCTIX funds to King Street Capital. What does this move mean for investors and the funds' strategy?

With a seasoned regulatory expert at the helm, Arletta Pharma is betting on its dual-action therapy, Lybrido, to transform the underserved FSIAD market.